about our programs
Portage has built a portfolio of six technology platforms initially yielding 14 candidates that uniquely target different cancer resistance pathways.
We’re leading scientists and clinicians through the development of immunotherapies that augment responses in immunogenic tumors and help initiate a response in non-immunogenic tumors. The flagship platform within our portfolio is our small molecule invariant natural killer T-cell (iNKT) engagers, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Our portfolio also includes small molecule adenosine inhibitors (PORT-6, PORT-7, PORT-8 and PORT-9), which represent a comprehensive exploration of how targeting the adenosine pathway could improve response in multiple indications. See current progress on our programs below.